Gabriella Miller Enhanced Delivery Immunotherapy Trial
Phase 1 Feasibility Trial of Repeated Convection Enhanced Delivery of HDAC Inhibitor MTX110 (Panobinostat) under real time image guidance for the Treatment of Children with Malignant Midline Gliomas
Dr. Mueller hypothesized that treatment options continue to fail for children with malignant midline gliomas because of the blood-brain and blood-tumor barrier. Her first of its kind trial in the U.S. could overcome this by repeated and direct surgical injection of an immunotherapy agent using real-time MRI guidance to ensure medication reaches the tumor.
This Project By The Numbers
Years Active2 years
InstitutionUniversity of California at San Fransisco, Benioff Children’s Hospital